TNFSF8

Summary

TNFSF8 (TNF superfamily member 8, HGNC:11938) is a protein-coding gene on chromosome 9q32-q33.1, encoding Tumor necrosis factor ligand superfamily member 8 (P32971). Cytokine that binds to TNFRSF8/CD30.

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. The engagement of this cytokine expressed on B cell surface plays an inhibitory role in modulating Ig class switch. This cytokine was shown to enhance cell proliferation of some lymphoma cell lines, while to induce cell death and reduce cell proliferation of other lymphoma cell lines. The pleiotropic biologic activities of this cytokine on different CD30+ lymphoma cell lines may play a pathophysiologic role in Hodgkin’s and some non-Hodgkin’s lymphomas. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 944 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 31 total
• MANE Select transcript: NM_001244

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11938
Approved symbol	TNFSF8
Name	TNF superfamily member 8
Location	9q32-q33.1
Locus type	gene with protein product
Status	Approved
Aliases	CD153
Ensembl gene	ENSG00000106952
Ensembl biotype	protein_coding
OMIM	603875
Entrez	944

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000223795, ENST00000474301, ENST00000618336, ENST00000872160

RefSeq mRNA: 2 — MANE Select: NM_001244 NM_001244, NM_001252290

CCDS: CCDS6810, CCDS75884

Canonical transcript exons

ENST00000223795 — 4 exons

Exon	Start	End
ENSE00000722203	114905828	114905899
ENSE00000722204	114918096	114918138
ENSE00000806380	114930109	114930591
ENSE00001317619	114901145	114904325

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 90.25.

FANTOM5 (CAGE): breadth broad, TPM avg 9.2815 / max 415.1738, expressed in 444 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102183	4.6976	351
102186	4.1447	341
102184	0.1720	98
102185	0.1200	61
102181	0.0770	41
102182	0.0702	46

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	90.25	gold quality
leukocyte	CL:0000738	89.83	gold quality
mononuclear cell	CL:0000842	89.72	gold quality
granulocyte	CL:0000094	88.52	gold quality
blood	UBERON:0000178	87.07	gold quality
lymph node	UBERON:0000029	86.45	gold quality
vermiform appendix	UBERON:0001154	80.77	gold quality
superficial temporal artery	UBERON:0001614	80.72	gold quality
spleen	UBERON:0002106	79.72	gold quality
gall bladder	UBERON:0002110	78.62	gold quality
bone marrow	UBERON:0002371	77.08	gold quality
caecum	UBERON:0001153	74.94	gold quality
amniotic fluid	UBERON:0000173	73.61	gold quality
parietal pleura	UBERON:0002400	73.60	gold quality
endometrium epithelium	UBERON:0004811	73.35	silver quality
right lung	UBERON:0002167	72.25	gold quality
pleura	UBERON:0000977	72.24	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.91	gold quality
bone marrow cell	CL:0002092	71.57	gold quality
trabecular bone tissue	UBERON:0002483	71.22	gold quality
rectum	UBERON:0001052	71.01	gold quality
frontal pole	UBERON:0002795	70.99	silver quality
visceral pleura	UBERON:0002401	70.77	gold quality
thymus	UBERON:0002370	70.75	gold quality
paraflocculus	UBERON:0005351	70.60	silver quality
middle frontal gyrus	UBERON:0002702	70.17	silver quality
upper lobe of left lung	UBERON:0008952	69.99	gold quality
tonsil	UBERON:0002372	69.88	gold quality
colonic epithelium	UBERON:0000397	69.63	silver quality
upper lobe of lung	UBERON:0008948	69.31	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	16.71
E-ANND-3	yes	8.62
E-HCAD-29	no	3519.87

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

126 targeting TNFSF8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-577	99.78	69.13	2479

Literature-anchored findings (GeneRIF, showing 18)

• capability to up-regulate expression of CD30, release of soluble CD30 and production of IL-4 in pre-activated T cells upon co-culture (PMID:11728464)
• only in a subset of both benign and malignant thyroid nodules the interleukin-6/interleukin-6 receptor signal could be induced by the CD30 ligand/CD30 (PMID:12553555)
• CD30-L/CD30 and IL-6/IL-6R systems could play a major role in the pathogenesis of Graves’disease (GD), but the expression of CD30L/CD30 and IL-6/IL-6R in Hashimoto’s thyroiditis (HT) suggests that Th2 mechanisms are involved in tissue damage. (PMID:16372246)
• Mast cells were found to be the predominant CD30 ligand-positive (CD30L-positive) cell in the chronic inflammatory skin diseases psoriasis and atopic dermatitis. (PMID:16964309)
• results suggested a possible role of cd30 and cd30L in the pathogenesis of acute leukemia (PMID:18689277)
• CD153 antigen was expressed by synovial mast cells, and correlated with serum levels, in Rheumatoid Arthritis patients (PMID:19208589)
• Single nucleotide polymorphism in TNFSF8 gene is associated with bone disease in myeloma. (PMID:19657367)
• a possible role of novel TNFSF8 variants in susceptibility to lung cancer. (PMID:21292647)
• Positional candidate gene screening in the SPA2 locus allowed us to identify and replicate an association between a rare SNP located in TNFSF8 and spondylarthritis. (PMID:21480186)
• The TNFSF8 polymorphisms rs927374 and rs2295800 were associated with neutrophil count. This finding suggests that post-MI inflammatory response is genetically modulated. (PMID:22033252)
• a novel and unexpected role for CD30/CD30L that contributes to proinflammatory immune responses (PMID:22628304)
• circulant sCD30L is functionally active and that it may favor persistence of active inflammation by inducing apoptosis of CD30(+)T cells, known to down-modulate inflammation in rheumatoid synovitis. (PMID:24447865)
• The heritability of IgA levels is moderate and can partly be attributable to common variation in the CD30L locus. (PMID:24676358)
• soluble apoptosis markers as sFas-L, Caspase-9, Caspase-8 and sCD153 were significantly higher in stage III obesity patients compared obese patients without food allergy (PMID:25059065)
• TNFSF8 is an important leprosy T1R susceptibility gene. (PMID:25320285)
• Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs). (PMID:27105521)
• Polyfunctional CD153-expressing CD4 T cells are increased in latent Mycobacterium tuberculosis infection compared to active Tuberculosis. (PMID:30202016)
• Several genetic variants associated with systemic sclerosis in a Chinese Han population. (PMID:36301368)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tnfsf8	ENSMUSG00000028362
rattus_norvegicus	Tnfsf8	ENSRNOG00000048321

Protein

Protein identifiers

Tumor necrosis factor ligand superfamily member 8 — P32971 (reviewed: P32971)

Alternative names: CD30 ligand

All UniProt accessions (3): P32971, A0A087X228, Q52M88

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells.

Subunit / interactions. Homotrimer.

Subcellular location. Membrane.

Similarity. Belongs to the tumor necrosis factor family.

RefSeq proteins (2): NP_001235, NP_001239219 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006052	TNF_dom	Domain
IPR008983	Tumour_necrosis_fac-like_dom	Homologous_superfamily
IPR021184	TNF_CS	Conserved_site
IPR021185	TNF_CD30_ligand_type	Family
IPR053104	TNF_ligand_SF_member_8	Family

Pfam: PF00229

UniProt features (11 total): glycosylation site 5, topological domain 2, chain 1, disulfide bond 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P32971-F1	80.07	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 151–177

Glycosylation sites (5): 81, 109, 153, 189, 201

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5669034	TNFs bind their physiological receptors

MSigDB gene sets: 245 (showing top): TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, SA_MMP_CYTOKINE_CONNECTION, GOBP_CELL_CELL_SIGNALING, GOBP_LEUKOCYTE_PROLIFERATION, WANG_RESPONSE_TO_BEXAROTENE_DN, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_DEFENSE_RESPONSE_TO_GRAM_POSITIVE_BACTERIUM, GOBP_ALPHA_BETA_T_CELL_ACTIVATION, GOMF_CYTOKINE_ACTIVITY, GOBP_DEFENSE_RESPONSE_TO_BACTERIUM, GOMF_SIGNALING_RECEPTOR_BINDING

GO Biological Process (9): immune response (GO:0006955), cell-cell signaling (GO:0007267), regulation of T cell proliferation (GO:0042129), CD8-positive, alpha-beta T cell differentiation (GO:0043374), positive regulation of transcription by RNA polymerase II (GO:0045944), defense response to Gram-positive bacterium (GO:0050830), cell communication (GO:0007154), signal transduction (GO:0007165), signaling (GO:0023052)

GO Molecular Function (4): signaling receptor binding (GO:0005102), cytokine activity (GO:0005125), tumor necrosis factor receptor binding (GO:0005164), protein binding (GO:0005515)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
TNFR2 non-canonical NF-kB pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	2
signaling	2
cellular process	2
immune system process	1
response to stimulus	1
T cell proliferation	1
regulation of lymphocyte proliferation	1
regulation of T cell activation	1
CD8-positive, alpha-beta T cell activation	1
alpha-beta T cell differentiation	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
defense response to bacterium	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of biological process	1
protein binding	1
receptor ligand activity	1
tumor necrosis factor receptor superfamily binding	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1520 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TNFSF8	TNFRSF8	P28908	999
TNFSF8	TNFRSF4	P43489	926
TNFSF8	CD27	P26842	920
TNFSF8	TNFSF15	O95150	876
TNFSF8	CD40	P25942	845
TNFSF8	TNFSF4	P23510	835
TNFSF8	TNFRSF9	Q07011	827
TNFSF8	TNFRSF6B	O95407	708
TNFSF8	CXCL8	P10145	703
TNFSF8	CD40LG	P29965	700
TNFSF8	TNF	P01375	698
TNFSF8	TNFRSF1A	P19438	671
TNFSF8	TNFRSF14	Q92956	660
TNFSF8	CD70	P32970	620
TNFSF8	TNFSF9	P41273	608

IntAct

15 interactions, top by confidence:

A	B	Type	Score
TNFSF8	TOR1B	psi-mi:“MI:0914”(association)	0.640
TNFSF8	TNFRSF8	psi-mi:“MI:0915”(physical association)	0.610
TNFSF8	TNFRSF8	psi-mi:“MI:0407”(direct interaction)	0.610
BMP10	TNFSF8	psi-mi:“MI:0915”(physical association)	0.560
TNFSF8	CXCL9	psi-mi:“MI:0915”(physical association)	0.560
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
AP5S1	AP5Z1	psi-mi:“MI:0914”(association)	0.530
PSG4	TNFSF8	psi-mi:“MI:0915”(physical association)	0.400
TNFSF8	NME4	psi-mi:“MI:0914”(association)	0.350
BMP10	TNFSF8	psi-mi:“MI:0915”(physical association)	0.000
CXCL9	TNFSF8	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (172): DCBLD1 (Affinity Capture-MS), CDON (Affinity Capture-MS), F5 (Affinity Capture-MS), RYK (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), NEK3 (Affinity Capture-MS), ULBP2 (Affinity Capture-MS), ATR (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), EFNB3 (Affinity Capture-MS), HBA2 (Affinity Capture-MS), ULBP1 (Affinity Capture-MS), TNFSF9 (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPN2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GSZ0, A5PK14, A6QQC6, B7ZWI3, C8AW46, C8AW47, O00453, O08843, O95976, P04235, P08920, P08921, P0C6B7, P21757, P30204, P32971, P32972, P86045, P86176, Q05585, Q16655, Q29102, Q2HRD5, Q3SYX1, Q3T113, Q3UQS2, Q3UU41, Q3UU67, Q4VAH7, Q4W815, Q5E9I3, Q62875, Q6AXS2, Q6EBC2, Q6UWF3, Q6UWW9, Q6UXZ0, Q6XQ84, Q6ZUJ8, Q80UL9

Diamond homologs: P32971, P32972

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

424 predictions. Top by Δscore:

Variant	Effect	Δscore
9:114904321:TGCCA:T	acceptor_gain	1.0000
9:114904323:CCA:C	acceptor_gain	1.0000
9:114904324:CA:C	acceptor_gain	1.0000
9:114904324:CAC:C	acceptor_gain	1.0000
9:114904326:C:CC	acceptor_gain	1.0000
9:114918091:CTTA:C	donor_loss	1.0000
9:114918092:TTAC:T	donor_loss	1.0000
9:114918093:TA:T	donor_loss	1.0000
9:114918094:ACCT:A	donor_gain	1.0000
9:114918095:C:CA	donor_loss	1.0000
9:114918095:CCTC:C	donor_gain	1.0000
9:114918097:T:TA	donor_gain	1.0000
9:114930107:ACCGT:A	donor_gain	1.0000
9:114930108:CCGTC:C	donor_gain	1.0000
9:114904322:GCCA:G	acceptor_gain	0.9900
9:114904323:CCAC:C	acceptor_gain	0.9900
9:114904326:CTAGA:C	acceptor_loss	0.9900
9:114905897:TTCC:T	acceptor_loss	0.9900
9:114905898:TCCT:T	acceptor_loss	0.9900
9:114905899:CCT:C	acceptor_loss	0.9900
9:114905900:C:CC	acceptor_gain	0.9900
9:114905900:CTA:C	acceptor_loss	0.9900
9:114905901:T:A	acceptor_loss	0.9900
9:114908637:C:T	acceptor_gain	0.9900
9:114918139:C:CC	acceptor_gain	0.9900
9:114918139:CT:C	acceptor_loss	0.9900
9:114918140:T:A	acceptor_loss	0.9900
9:114930102:CACTT:C	donor_loss	0.9900
9:114930103:ACTTA:A	donor_loss	0.9900
9:114930104:CTTAC:C	donor_loss	0.9900

AlphaMissense

1530 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:114904195:A:C	F147L	0.992
9:114904195:A:T	F147L	0.992
9:114904197:A:G	F147L	0.992
9:114904293:A:G	W115R	0.992
9:114904293:A:T	W115R	0.992
9:114904291:C:A	W115C	0.989
9:114904291:C:G	W115C	0.989
9:114904019:A:T	V206D	0.988
9:114904196:A:G	F147S	0.988
9:114904209:A:G	C143R	0.987
9:114904202:A:G	L145P	0.984
9:114904025:A:T	I204K	0.983
9:114904163:A:G	L158P	0.983
9:114905833:A:G	L102P	0.981
9:114903967:A:C	N223K	0.979
9:114903967:A:T	N223K	0.979
9:114904107:A:G	C177R	0.979
9:114904151:A:G	L162P	0.978
9:114904106:C:G	C177S	0.977
9:114904107:A:T	C177S	0.977
9:114904196:A:C	F147C	0.977
9:114930159:A:G	C49R	0.977
9:114904106:C:T	C177Y	0.975
9:114904023:A:G	S205P	0.974
9:114904221:A:C	Y139D	0.973
9:114904207:G:C	C143W	0.972
9:114904067:A:G	L190P	0.971
9:114904025:A:C	I204R	0.970
9:114904105:A:C	C177W	0.968
9:114904292:C:G	W115S	0.968

dbSNP variants (sampled 300 via entrez): RS1000084691 (9:114893685 G>C,T), RS1000198621 (9:114898834 T>C), RS1000198727 (9:114906501 G>A,T), RS1000254033 (9:114913239 T>A), RS1000375231 (9:114899857 G>A), RS1000423174 (9:114905059 G>A), RS1000427435 (9:114899602 G>A), RS1000561466 (9:114928176 C>T), RS1000654167 (9:114906168 A>G), RS1000769513 (9:114904679 G>A,C), RS1000891442 (9:114895076 T>C), RS1001023180 (9:114922533 T>C), RS1001085385 (9:114930212 A>C,G), RS1001341771 (9:114894864 A>G), RS1001382090 (9:114898486 G>A)

Disease associations

OMIM: gene MIM:603875 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST000879_9	Crohn’s disease	1.000000e-15
GCST000964_9	Ulcerative colitis	6.000000e-12
GCST001725_101	Inflammatory bowel disease	3.000000e-32
GCST001785_11	Crohn’s disease	5.000000e-46
GCST003602_12	Inflammatory bowel disease	2.000000e-27
GCST004302_3	Primary biliary cholangitis	1.000000e-29
GCST004600_80	Eosinophil percentage of white cells	5.000000e-13
GCST004606_12	Eosinophil count	3.000000e-11
GCST004617_171	Eosinophil percentage of granulocytes	1.000000e-13
GCST004623_127	Neutrophil percentage of granulocytes	5.000000e-13
GCST004624_136	Sum eosinophil basophil counts	2.000000e-10
GCST004863_3	Mosquito bite size	2.000000e-07
GCST005537_174	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	1.000000e-14
GCST007036_4	Primary biliary cholangitis	2.000000e-26
GCST007216_1	Crohn’s disease	3.000000e-26
GCST008568_10	IgA levels	7.000000e-08
GCST008572_10	Composite immunoglobulin trait (IgA/IgG)	2.000000e-07
GCST90002381_480	Eosinophil count	2.000000e-24
GCST90002382_273	Eosinophil percentage of white cells	2.000000e-28
GCST90010715_11	Arthritis (juvenile idiopathic)	8.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004842	eosinophil count
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0005090	basophil count
EFO:0008378	mosquito bite reaction size measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
(+)-JQ1 compound	decreases expression	2
Arsenic Trioxide	increases expression	2
Nickel	increases expression	2
potassium perchlorate	increases expression	1
VX-agent	increases expression	1
3,3’-diindolylmethane	increases expression	1
sodium arsenite	affects methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
usnic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
motexafin gadolinium	decreases reaction, increases expression	1
abrine	increases expression	1
brevetoxin 2	increases expression	1
PF 3758309	decreases expression	1
Erlotinib Hydrochloride	affects cotreatment, affects expression	1
Zoledronic Acid	increases expression	1
Gemcitabine	affects cotreatment, affects expression	1
alpha-Chlorohydrin	decreases expression	1
Arsenic	affects cotreatment, decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Environmental Pollutants	affects expression	1
Fluorides	decreases expression, affects cotreatment	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Menthol	decreases expression	1
Paraquat	decreases expression	1
Phthalic Acids	decreases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.